Citius Oncology Receives Nasdaq Delisting Warning for Sub-$1.00 Bid Price, Faces October Deadline

summarizeSummary

Citius Oncology received a Nasdaq delisting notice for failing to meet the minimum bid price requirement, with a compliance deadline of October 19, 2026.

check_boxKey Events

• Nasdaq Delisting Warning Received

  On April 22, 2026, Nasdaq notified Citius Oncology, Inc. that its common stock bid price had closed below the minimum $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

• 180-Day Compliance Period

  The company has until October 19, 2026, to regain compliance. This requires the stock's bid price to close at $1.00 or more for a minimum of ten consecutive business days.

• Potential for Reverse Stock Split

  If compliance is not regained by the deadline, the company may be eligible for an additional 180-day period if it meets other listing standards and intends to cure the deficiency, potentially through a reverse stock split.

• No Immediate Effect on Listing

  The notice does not immediately affect the listing of the company's common stock, which will continue to trade on the Nasdaq Capital Market under the symbol 'CTOR'.

auto_awesomeAnalysis

Citius Oncology has received a formal notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price requirement. This is a critical development, especially given the company's previously disclosed 'going concern' warning and limited cash runway until May 2026. The delisting notice adds significant pressure and uncertainty, potentially impacting investor confidence and the company's ability to raise future capital. While the company has 180 days to regain compliance, often through a reverse stock split, such actions can be dilutive and may not provide a long-term solution without fundamental business improvements. Investors should monitor the company's strategy to address this deficiency and its overall financial health closely.